Pharmaceutical Commerce - May/June 2012

Oncology combines some of the most life-changing therapeutic events with the most complex commercialization pathways. Rising costs of treatments simply add to the tension

Biopharma remains a bright spot in US and international economic activity, even while the overall outlook remains cloudy

Latest annual Progressions report highlights the shift to healthy behaviors

Tomorrow's healthcare market, driven by consumer choice and outcomes-driven economics, will create new supply chain models

Merger is not expected to affect specialty-distribution agreements negatively

Ten-year BLS projection sees a healthy industry ahead

Patient office visits, prescription usage continued to decline

Pharma industry serves best as underwriter of healthcare providers' efforts

Covis Pharmaceuticals' business model is to acquire distribution rights to low-volume drugs

Applying a consistent framework to choose locations can help optimize R&D and drive cost reduction for pharmaceutical companies of all sizes

Compiling and maintaining lists of healthcare provider contacts is a bigger and more important task than ever